Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for rheumatoid arthritis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on rheumatoid arthritis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on rheumatoid arthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
[Baricitinib (rheumatoidarthritis) - benefit assessment according to õ35a Social Code Book V] Baricitinib (rheumatoidearthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-14 [Baricitinib (rheumatoidarthritis) - benefit assessment according to §35a Social Code Book V] Baricitinib (rheumatoidearthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-14 [Baricitinib (rheumatoidarthritis) - benefit assessment according to §35a Social Code Book V (...) ] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Baricitinib (rheumatoidearthritis): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-14. [Baricitinib (rheumatoidarthritis) - benefit assessment
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoidarthritis: secondary analyses from the RA-BEAM study To assess the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoidarthritis and an inadequate response to methotrexate (MTX).In this double-blind phase 3 study, patients were randomised 3:3:2 to placebo (n=488), baricitinib 4 mg once daily (n=487), or adalimumab 40 mg biweekly (n=330 (...) ) with background MTX. PROs included the SF-36, EuroQol 5-D (EQ-5D) index scores and visual analogue scale, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain and Work Productivity and Activity Impairment Questionnaire-RheumatoidArthritis (WPAI-RA), and measures collected in electronic patient daily diaries: duration and severity of morning joint
Long-Term Effectiveness of Adalimumab in Patients with RheumatoidArthritis: An Observational Analysis from the Corrona RheumatoidArthritis Registry Current recommendations for the management of rheumatoidarthritis (RA) focus on a treat-to-target approach with the objective of maximizing long-term health-related quality-of-life in patients with RA. Published studies from randomized clinical trials have reported limited data regarding the long-term efficacy and safety of adalimumab in patients
Treatment with Biologicals in RheumatoidArthritis: An Overview Management and therapy of rheumatoidarthritis (RA) has been revolutionized by the development and approval of the first biological disease-modifying antirheumatic drugs (bDMARDs) targeting tumor necrosis factor (TNF) α at the end of the last century. Today, numerous efficacious agents with different modes of action are available and achievement of clinical remission or, at least, low disease activity is the target of therapy
Discontinuation of Biologic Therapy in RheumatoidArthritis: Analysis from the Corrona RA Registry Despite the availability of multiple effective therapies, discontinuation/switching of treatment is common for many patients with rheumatoidarthritis (RA). This study was designed to examine initiation of biologic disease-modifying anti-rheumatic drugs (bDMARDs) within the Consortium of Rheumatology Researchers of North America (Corrona) RA Registry, and characterize reasons
Switching From Immediate-Release to Delayed-Release Prednisone in Moderate to Severe RheumatoidArthritis: A Practice-Based Clinical Study Rheumatoidarthritis (RA) produces debilitating morning stiffness. Exogenous glucocorticoids can help with these symptoms when timed appropriately. Bedtime dosing of delayed-release prednisone (DR-prednisone) matches the rise of inflammatory cytokines before awakening and can improve stiffness and other RA symptoms. A prospective open-label study
Identification and Treatment Optimization of Comorbid Depression in RheumatoidArthritis Patients with rheumatoidarthritis (RA) suffer from high rates of depression but depression often remains undiagnosed and untreated among RA patients. Because of its high prevalence and its profound impact on functional disability and health-related quality of life, prompt recognition and management of comorbid depression is urgently needed in patients with RA. Rheumatologists face the challenge
Practical Management of Respiratory Comorbidities in Patients with RheumatoidArthritis Lung disease is one of the most common causes of extra-articular morbidity and mortality in patients with rheumatoidarthritis (RA). Development of pulmonary manifestations may be due to the systemic disease itself; to serious respiratory adverse events such as pneumonitis and infections secondary to therapy; or to lifestyle habits such as smoking. Rheumatologists often need to make important treatment
Acute coronary syndrome in new-onset rheumatoidarthritis: a population-based nationwide cohort study of time trends in risks and excess risks Acute coronary syndrome (ACS) and other cardiovascular diseases are the main drivers of the increased morbidity and preterm mortality in rheumatoidarthritis (RA). ACS in RA has been linked to inflammation and RA severity. During recent years and with new therapeutic options and treat-to-target strategies, increasing efforts have been made to reach RA
The journey of rheumatoidarthritis patients: a review of reported lag times from the onset of symptoms Even after achieving tremendous advances in diagnosis and treatment of rheumatoidarthritis (RA), many of the patients undergo delays in diagnosis and initiation of treatment, which leads to worsening of the condition and poor prognosis.The objective of this study was to perform a literature review to quantify the lag times in diagnosis and treatment of RA and study the reported factors
Practical Management of Cardiovascular Comorbidities in RheumatoidArthritis Cardiovascular (CV) comorbidities are a frequent extra-articular manifestation of rheumatoidarthritis (RA). Cardiovascular disease (CVD) with accelerated atherosclerosis is a major cause of morbidity and mortality in patients with RA. Subclinical CVD may be present since the early phase of RA. Not only traditional but also non-traditional CV risk factors are involved in the pathogenesis of RA-related CVD. Due
Repository corticotropin injection as adjunctive therapy in patients with rheumatoidarthritis who have failed previous therapies with at least three different modes of action Many types of treatment are available for patients with rheumatoidarthritis (RA), however, some patients fail to achieve remission. This report aims to determine the safety and efficacy of using repository corticotropin injection (RCI) as an adjunctive therapy in patients with RA refractory to at least three therapeutics
The Effect Size of Fibromyalgia on PG-VAS in RheumatoidArthritis Patients. Adjustment Proposal in DAS28-ESR: Letter to the Editor regarding Challa, D.N.V., Crowson, C.S. & Davis, J.M. Rheumatol Ther (2017) 4: 201. doi:10.1007/s40744-017-0063-5 28685293 2018 11 13 2198-6576 4 2 2017 Dec Rheumatology and therapy Rheumatol Ther The Effect Size of Fibromyalgia on PG-VAS in RheumatoidArthritis Patients. Adjustment Proposal in DAS28-ESR: Letter to the Editor regarding Challa, D.N.V., Crowson, C.S (...) Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Avenida Gonzalitos 235 Norte, Monterrey, Nuevo León, México. Esquivel-Valerio Jorge Antonio JA Servicio de Reumatología, Departamento de Medicina Interna, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Avenida Gonzalitos 235 Norte, Monterrey, Nuevo León, México. eng Letter 2017 07 06 England Rheumatol Ther 101674543 2198-6576 Fibromyalgia Rheumatoidarthritis 2017 05 28 2017 7 8 6 0
Tropical pyomyositis caused by Klebsiella pneumoniae with rheumatoidarthritis 29657883 2018 11 30 2147-9720 5 1 2018 Mar European journal of rheumatology Eur J Rheumatol Tropical pyomyositis caused by Klebsiella pneumoniae with rheumatoidarthritis. 83-84 10.5152/eurjrheum.2017.160126 Carneiro Juliana Brandão Pinto JBP http://orcid.org/0000-0001-7184-0582 Department of Rheumatology, Getúlio Vargas University Hospital (HUGV), Federal University of Amazon School of Medicine (UFAM), Manaus
A population-based cohort study of rheumatoidarthritis-associated interstitial lung disease: comorbidity and mortality To compare mortality risks in patients with rheumatoidarthritis-associated interstitial lung disease (RA-ILD) and patients with RA without ILD.Matched cohort study.The study was conducted in Denmark, using nationwide, prospectively collected data.Among patients with RA diagnosed between 2004 and 2016, 679 patients with RA-ILD were matched for birth year, gender and age at RA
Evaluation of the diagnostic accuracy of hand and foot MRI for early RheumatoidArthritis To assess the diagnostic value of MRI for early RA. In some RA patients, a classifiable diagnosis cannot be made at first presentation; these patients present with unclassified arthritis (UA). The use of MRI for early diagnosis of RA is recommended, yet the evidence for its reliability is limited.MRI of hand and foot was performed in 589 early arthritis patients included in the Leiden Early Arthritis
Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoidarthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial Tumour necrosis factor inhibitors (TNFi) are effective in rheumatoidarthritis (RA), but disadvantages include adverse events (AEs) and high costs. This can be improved by disease activity-guided dose reduction (DR). We aimed to assess long-term outcomes of TNFi DR in RA by using 3-year data
Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoidarthritis: a randomised, double-blind, phase III equivalence study ABP 501 is a Food and Drug Administration-approved biosimilar to adalimumab; structural, functional and pharmacokinetic evaluations have shown that the two are highly similar. We report results from a phase III study comparing efficacy, safety and immunogenicity between ABP 501 and adalimumab.In this randomised (...) , double-blind, active comparator-controlled, 26-week equivalence study, patients with moderate to severe active rheumatoidarthritis (RA) despite methotrexate were randomised (1:1) to ABP 501 or adalimumab (40 mg) every 2 weeks. Primary endpoint was risk ratio (RR) of ACR20 between groups at week 24. Primary hypothesis that the treatments were equivalent would be confirmed if the 90% CI for RR of ACR20 at week 24 fell between 0.738 and 1.355, demonstrating that ABP 501 is similar to adalimumab